Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

ABSTRACT:

Background

The use of anthracyclines is limited by the occurrence of cardiotoxicity. In an effort to prevent this cardiotoxicity, different anthracycline derivates have been studied.

Objectives

To determine the occurrence of cardiotoxicity with the use of different anthracycline derivates in cancer patients.

Search strategy

We searched The Cochrane Central Register of Controlled Trials (CENTRAL), (The Cochrane Library, Issue 2, 2009), MEDLINE (1966 to 29 May 2009) and EMBASE (1980 to 2 June 2009). In addition, we searched reference lists of relevant articles, conference proceedings and ongoing-trials-databases.

Selection criteria

Randomised controlled trials (RCTs) in which different anthracycline derivates were compared in cancer patients (children and adults)

SUBMITTER: van Dalen EC 

PROVIDER: S-EPMC6457588 | biostudies-literature | 2010 May

REPOSITORIES: biostudies-literature